You are here
Treatment patterns and outcomes in “real world” patients (pts) with metastatic urothelial cancer (UC).
J Clin Oncol 31, 2013 (suppl; abstr 4525)
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: Most studies reporting outcomes of pts with metastatic UC are derived from clinical trial data, potentially limiting the breadth/generalizability of the findings. To explore patterns of care/outcomes in “real world” pts, we initiated an international retrospective cohort study. Methods: Data were collected via an electronic data capture platform from 23 centers. Eligible pts had UC (at least muscle-invasive) and were initially evaluated from 1/1/2006-1/1/2011. Parameters were subjected to regression analysis to identify prognostic variables. Results: By 12/18/12, 1905 pts were enrolled. Among 1077 with metastatic UC, median age was 67 (IQR 60-75), 80% were male, 87% had bladder primary tumors, and 33% received perioperative chemotherapy. Only 758 (70%) received 1st-line chemotherapy for metastatic UC: cisplatin-based (51%), carboplatin-based (29%), non-platinum single-agent (16%), and non-platinum multi-agent (4%). The median survival from date of diagnosis of metastatic UC was 5.2 months (95% CI 4.4-6.5) and 16.1 months (95% CI 15.1-17.5) for pts who did and did not receive 1st-line chemotherapy, respectively [13.9 months (95% CI 12.78-14.98) from start of chemotherapy for latter group]. Among pts receiving 1st-line chemotherapy, univariable analysis revealed gender, primary tumor site, removal of primary, creatinine clearance, LDH, and hgb were not significantly associated with survival whereas smoking status, performance status, perioperative chemotherapy, metastatic sites, study site and chemotherapy regimen were. The multivariable analysis is shown in the Table. Conclusions: The current analysis identifies previously unrecognized prognostic factors in an international cohort of “real world” pts with metastatic UC treated with 1st-line chemotherapy. A large subset of pts with metastatic UC receives no chemotherapy.
|Smoking history||Current vs. never/former||1.48||1.12-1.95||0.006|
|Perioperative chemotherapy||No vs. yes||0.63||0.46-0.86||0.004|
|# of visceral metastatic sites||1 vs. 0||1.76||1.25-2.47||0.001|
|≥2 vs. 0||2.23||1.56-3.20||<0.001|
|ECOG PS||1 vs. 0||1.73||1.29-2.32||<0.001|
|≥2 vs. 0||2.98||2.02-4.40||<0.001|
Abstracts by M. D. Galsky:
Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.Category: Genitourinary Cancer - Prostate Cancer
Meeting: 2014 Genitourinary Cancers Symposium
| Abstract No: 59
Category: Genitourinary Cancer - Prostate Cancer
Geographic and racial disparities in the utilization of low-volume cystectomy hospitals for bladder cancer.
Educational Book Articles by M. D. Galsky:
Presentations by M. D. Galsky:
Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC).Session: General Poster Session A: Prostate Cancer (General Poster Session)
Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.Session: General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma (General Poster Session)
Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer.Session: General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma (General Poster Session)